Emil Scosyrev1, Edward M Messing2, Richard Sylvester3, Steven Campbell4, Hendrik Van Poppel5. 1. Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. 2. Department of Urology, University of Rochester Medical Center, Rochester, NY, USA. Electronic address: Edward_Messing@urmc.rochester.edu. 3. Department of Biostatistics, EORTC Headquarters, Brussels, Belgium. 4. Department of Urology, Cleveland Clinic, Cleveland, OH, USA. 5. Department of Urology, University Hospital K.U. Leuven, Leuven, Belgium.
Abstract
BACKGROUND: In the European Organization for Research and Treatment of Cancer (EORTC) randomized trial 30904, nephron-sparing surgery (NSS) was associated with reduced overall survival compared with radical nephrectomy (RN) over a median follow-up of 9.3 yr (hazard ratio: 1.50; 95% confidence interval [CI], 1.03-2.16). OBJECTIVE: To examine the impact of NSS relative to RN on kidney function in EORTC 30904. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 international randomized trial was conducted in patients with a small (≤5 cm) renal mass and normal contralateral kidney who were enrolled from March 1992 to January 2003. INTERVENTION: Patients were randomized to RN (n=273) or NSS (n=268). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Follow-up estimated glomerular filtration rates (eGFR; milliliters per minute per 1.73 m(2)) were recorded for 259 subjects in the RN arm and 255 subjects in the NSS arm. Percentages of subjects developing at least moderate renal dysfunction (eGFR <60), advanced kidney disease (eGFR <30), or kidney failure (eGFR <15) were calculated for each treatment arm based on the lowest recorded follow-up eGFR (intent-to-treat analysis). RESULTS AND LIMITATIONS: With a median follow-up of 6.7 yr, eGFR <60 was reached by 85.7% with RN and 64.7% with NSS, with a difference of 21.0% (95% CI, 13.8-28.3); eGFR <30 was reached by 10.0% with RN and 6.3% with NSS, with a difference of 3.7% (95% CI, -1.0 to 8.5); and eGFR <15 was reached by 1.5% with RN and 1.6% with NSS, with a difference of -0.1% (95% CI, -2.2 to 2.1). Lack of longer follow-up for eGFR is a limitation of these analyses. CONCLUSIONS: Compared with RN, NSS substantially reduced the incidence of at least moderate renal dysfunction (eGFR <60), although with available follow-up the incidence of advanced kidney disease (eGFR <30) was relatively similar in the two treatment arms, and the incidence of kidney failure (eGFR <15) was nearly identical. The beneficial impact of NSS on eGFR did not result in improved survival in this study population. REGISTRATION: EORTC trial 30904; ClinicalTrials.gov identifier NCT00002473.
RCT Entities:
BACKGROUND: In the European Organization for Research and Treatment of Cancer (EORTC) randomized trial 30904, nephron-sparing surgery (NSS) was associated with reduced overall survival compared with radical nephrectomy (RN) over a median follow-up of 9.3 yr (hazard ratio: 1.50; 95% confidence interval [CI], 1.03-2.16). OBJECTIVE: To examine the impact of NSS relative to RN on kidney function in EORTC 30904. DESIGN, SETTING, AND PARTICIPANTS: This phase 3 international randomized trial was conducted in patients with a small (≤5 cm) renal mass and normal contralateral kidney who were enrolled from March 1992 to January 2003. INTERVENTION: Patients were randomized to RN (n=273) or NSS (n=268). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Follow-up estimated glomerular filtration rates (eGFR; milliliters per minute per 1.73 m(2)) were recorded for 259 subjects in the RN arm and 255 subjects in the NSS arm. Percentages of subjects developing at least moderate renal dysfunction (eGFR <60), advanced kidney disease (eGFR <30), or kidney failure (eGFR <15) were calculated for each treatment arm based on the lowest recorded follow-up eGFR (intent-to-treat analysis). RESULTS AND LIMITATIONS: With a median follow-up of 6.7 yr, eGFR <60 was reached by 85.7% with RN and 64.7% with NSS, with a difference of 21.0% (95% CI, 13.8-28.3); eGFR <30 was reached by 10.0% with RN and 6.3% with NSS, with a difference of 3.7% (95% CI, -1.0 to 8.5); and eGFR <15 was reached by 1.5% with RN and 1.6% with NSS, with a difference of -0.1% (95% CI, -2.2 to 2.1). Lack of longer follow-up for eGFR is a limitation of these analyses. CONCLUSIONS: Compared with RN, NSS substantially reduced the incidence of at least moderate renal dysfunction (eGFR <60), although with available follow-up the incidence of advanced kidney disease (eGFR <30) was relatively similar in the two treatment arms, and the incidence of kidney failure (eGFR <15) was nearly identical. The beneficial impact of NSS on eGFR did not result in improved survival in this study population. REGISTRATION: EORTC trial 30904; ClinicalTrials.gov identifier NCT00002473.
Authors: Matthew R Danzig; Peter Chang; Andrew A Wagner; Mohamad E Allaf; James M McKiernan; Phillip M Pierorazio Journal: Curr Urol Rep Date: 2016-01 Impact factor: 3.092
Authors: Maria C Mir; Nicola Pavan; Umberto Capitanio; Alessandro Antonelli; Ithaar Derweesh; Oscar Rodriguez-Faba; Estefania Linares; Toshio Takagi; Koon H Rha; Christian Fiori; Tobias Maurer; Chao Zang; Alexandre Mottrie; Paolo Umari; Jean-Alexandre Long; Gaelle Fiard; Cosimo De Nunzio; Andrea Tubaro; Andrew T Tracey; Matteo Ferro; Ottavio De Cobelli; Salvatore Micali; Luigi Bevilacqua; João Torres; Luigi Schips; Roberto Castellucci; Ryan Dobbs; Giuseppe Quarto; Pierluigi Bove; Antonio Celia; Bernardino De Concilio; Carlo Trombetta; Tommaso Silvestri; Alessandro Larcher; Francesco Montorsi; Carlotta Palumbo; Maria Furlan; Ahmet Bindayi; Zachary Hamilton; Alberto Breda; Joan Palou; Alfredo Aguilera; Kazunari Tanabe; Ali Raheem; Thomas Amiel; Bo Yang; Estevão Lima; Simone Crivellaro; Sisto Perdona; Caterina Gregorio; Giulia Barbati; Francesco Porpiglia; Riccardo Autorino Journal: World J Urol Date: 2019-04-01 Impact factor: 4.226
Authors: John T Leppert; Harsha R Mittakanti; I-Chun Thomas; Remy W Lamberts; Geoffrey A Sonn; Benjamin I Chung; Eila C Skinner; Todd H Wagner; Glenn M Chertow; James D Brooks Journal: Urology Date: 2016-09-12 Impact factor: 2.649
Authors: Scott E Eggener; Melanie A Clark; Sergey Shikanov; Benjamin Smith; Matthew Kaag; Paul Russo; Jeffrey C Wheat; J Stuart Wolf; Surena F Matin; William C Huang; Miriam Harel; Joseph Cambio; Arieh L Shalhav; Jay D Raman Journal: World J Urol Date: 2014-05-10 Impact factor: 4.226